Direkt zum Inhalt
Merck

1544508

USP

Piroxicam

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

4-Hydroxy-2-methyl-3-(pyrid-2-yl-carbamoyl)-2H-1,2-benzothiazin-1,1-dioxid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C15H13N3O4S
CAS-Nummer:
Molekulargewicht:
331.35
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

piroxicam

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

CN1C(C(=O)Nc2ccccn2)=C(O)c3ccccc3S1(=O)=O

InChI

1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)

InChIKey

QYSPLQLAKJAUJT-UHFFFAOYSA-N

Angaben zum Gen

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Piroxicam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Piroxicam Capsules
  • Piroxicam Compounded Cream
  • Piroxicam Compounded Oral Suspension

Biochem./physiol. Wirkung

Cyclooxygenase-Inhibitor

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Piktogramme

Skull and crossbonesHealth hazard

Signalwort

Danger

H-Sätze

Gefahreneinstufungen

Acute Tox. 3 Oral - STOT RE 2 Oral

Zielorgane

Gastrointestinal tract

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

J Y Reginster et al.
European journal of rheumatology and inflammation, 12(4), 38-46 (1993-01-01)
Analgesics continue to be the mainstay of therapy in osteoarthritis. Non-steroidal anti-inflammatory drugs (NSAIDs) play an important role, particularly where there is a significant inflammatory component to the osteoarthritis. Piroxicam-beta-cyclodextrin (PBC) is a new formulation in which piroxicam has been
D L Earnest et al.
Journal of cellular biochemistry. Supplement, 16I, 156-166 (1992-01-01)
Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) widely used for treatment of inflammatory arthritis. Recent experimental and clinical studies suggest that piroxicam, as well as other NSAIDs, may be useful for chemoprevention of colon cancer. While there is less information
C Scarpignato
Current medicinal chemistry, 20(19), 2415-2437 (2013-02-12)
Although NSAIDs are very effective drugs, their use is associated with a broad spectrum of adverse reactions in the liver, kidney, cardiovascular (CV) system, skin and gut. Gastrointestinal (GI) side effects are the most common and constitute a wide clinical
S Warrington
European journal of rheumatology and inflammation, 12(4), 29-37 (1993-01-01)
Piroxicam-beta-cyclodextrin (PBC), a complex of piroxicam with beta-cyclodextrin, was developed with the aim of improving the hydrosolubility and bioavailability of piroxicam. The complex is more rapidly absorbed, with a consequent reduction in the time of contact of piroxicam with the
M G Northway et al.
Cancer, 66(11), 2300-2305 (1990-12-01)
This study evaluated the effects of the nonsteroidal antiinflammatory agent piroxicam on chronic radiation proctitis in the rat. Forty female Wistar rats received a 2250-cGy dose of irradiation to the distal 2 cm of the colon. Twenty received piroxicam 8.0

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.